Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

SOUTHERN LAB PARTNERS, LLC

NPI: 1164775862 · BIRMINGHAM, AL 35233 · Clinical Medical Laboratory · NPI assigned 10/18/2012

$14.38M
Total Medicaid Paid
244,178
Total Claims
219,073
Beneficiaries
76
Codes Billed
2018-01
First Month
2024-06
Last Month

Provider Details

Authorized OfficialPOTTER, ASHLEY (PARTNER)
Parent OrganizationFALCON HEALTH CARE SOLUTIONS, LLC
NPI Enumeration Date10/18/2012

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 67,835 $4.09M
2019 72,191 $4.22M
2020 41,543 $2.33M
2021 39,086 $2.32M
2022 12,397 $769K
2023 8,253 $469K
2024 2,873 $171K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism 30,342 27,017 $4.19M
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets 17,358 15,989 $3.38M
87801 Infectious agent detection by nucleic acid; amplified probe, multiple organisms 20,202 18,103 $1.28M
U0004 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r 15,712 12,781 $935K
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets 14,762 13,540 $638K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 4,685 4,432 $624K
87507 2,709 2,484 $476K
87581 19,015 17,372 $473K
87149 15,862 14,338 $328K
87561 12,069 11,151 $297K
87651 Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe 11,822 11,048 $294K
87486 9,536 8,593 $232K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 1,455 1,378 $152K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 6,232 5,684 $116K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 2,204 2,059 $110K
87631 1,529 1,279 $82K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 1,377 1,319 $62K
87799 4,472 3,685 $61K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe 1,694 1,419 $58K
87592 1,397 1,179 $57K
87498 2,740 2,472 $54K
87147 11,653 10,885 $53K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed 1,997 1,852 $45K
84443 Thyroid stimulating hormone (TSH) 2,420 2,234 $45K
80053 Comprehensive metabolic panel 3,830 3,501 $37K
87511 1,640 1,395 $36K
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe 1,960 1,443 $33K
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc 1,010 909 $33K
85025 Blood count; complete (CBC), automated, and automated differential WBC count 3,777 3,368 $30K
87503 2,821 2,557 $26K
80061 Lipid panel 1,949 1,819 $22K
G2023 Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source 1,310 1,156 $19K
84439 2,184 1,976 $16K
83036 Hemoglobin; glycosylated (A1C) 1,627 1,506 $15K
87070 951 830 $9K
87634 170 156 $8K
82607 599 552 $7K
87077 883 794 $6K
84480 309 296 $4K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 49 43 $3K
82728 262 251 $3K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 719 394 $3K
84481 189 173 $3K
87481 94 28 $3K
86140 455 433 $2K
87086 Culture, bacterial; quantitative colony count, urine 453 269 $2K
87506 15 13 $1K
85652 427 399 $1K
83550 130 119 $1K
82746 106 98 $933.51
K1034 Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count 801 786 $906.24
83540 149 137 $886.40
87088 135 86 $840.40
83735 127 118 $688.52
87482 13 13 $660.00
87186 55 38 $586.18
84550 147 117 $582.00
87640 29 27 $568.94
87653 29 27 $568.94
36415 Collection of venous blood by venipuncture 917 457 $456.00
82247 78 51 $344.54
86689 14 14 $312.00
84146 13 12 $264.00
87184 47 26 $215.46
87081 91 75 $179.55
81000 49 42 $151.98
84436 81 79 $133.00
80048 Basic metabolic panel (calcium, ionized) 14 12 $77.00
86431 16 16 $75.06
86592 13 13 $60.00
87205 23 12 $58.59
85651 14 13 $48.91
81003 17 13 $30.00
82570 57 37 $6.00
87505 17 16 $0.00
87652 69 65 $0.00